Perspectives on Selected Hemophilia Research Presented at ISTH 2025: Nonfactor Replacement Therapies

Perspectives on Selected Hemophilia Research Presented at ISTH 2025: Nonfactor Replacement Therapies

By Annenberg Center for Health SciencesMedicineHealth & Fitness
Download on the App Store

Perspectives on Selected Hemophilia Research Presented at ISTH 2025: Nonfactor Replacement Therapies episodes

  • Conclusions

    Dr. von Drygalski shares her thoughts about the importance of this research and its relevance to clinical practice.

    1 min
  • Factor VIII Mimetics

    Abstract 4: Effectiveness of emicizumab in hemophilia A: A 4th interim analysis of the real-world study EMIIL

    Abstract 5: Prospective evaluation of a defined replacement protocol for peri-operative hemostasis in patients with severe hemophilia A with and without inhibitors on emicizumab prophylaxis undergoing elective major surgeries-final results. (EmiSurg Study)

    Abstract 6: FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab

    15 min
  • A Focus on Rebalancing Agents

    Abstract 1: Association of antithrombin levels with efficacy of fitusiran prophylaxis in people with hemophilia A or B with and without inhibitors: a predictive modeling approach

    Abstract 2: Annualized bleeding rates in hemophilia A/B and target joints: Concizumab explorer8 study

    Abstract 3: Long-term efficacy of marstacimab in participants with severe hemophilia A or B without inhibitors

    11 min

About Perspectives on Selected Hemophilia Research Presented at ISTH 2025: Nonfactor Replacement Therapies

From the publisher's feed

The treatment of persons with hemophilia continues to evolve, with important advancements that address limitations with factor replacement such as diminished efficacy in patients with inhibitors and…